Skip to main content
. Author manuscript; available in PMC: 2010 Nov 1.
Published in final edited form as: J Neurosci Res. 2009 Nov 1;87(14):3176–3185. doi: 10.1002/jnr.22137

Figure 1.

Figure 1

PLTP reduces levels of tau phosphorylated at threonine 231 in HCN2 cells. Cells were incubated without or with (2, 5 or 10 μg/ml) human rPLTP, and cell proteins (30 μg) were resolved using SDS-PAGE. A) Total tau in cells incubated for 48 hours in serum-free media. B) Levels of pTauThr231 in cells incubated for 48 hours in serum-free media. C) PLTP effect on levels of pTauThr231; results of three separate experiments, each performed in triplicate (n=9; *p<0.05 compared to control cells). D) Time-dependent changes in pTauThr231 levels in cells incubated without or with (5 μg/ml) human rPLTP for 6, 24 and 48h. E) pTauThr231 levels in cells incubated without or with (5 μg/ml) rPLTP for 48h under serum-free conditions, and in presence of serum. F) Time-dependent changes of pTauSer356 in cells incubated without or with rPLTP (5 μg/ml) for 6, 24 and 48h. G) Dose-dependent changes of pTauSer356 in cells incubated for 48h with 2, 5 or 10 μg/ml rPLTP. Antibodies against tau (total and phosphorylated) were used at 1:800, while anti-actin antibody was used at 1:12,000 dilution.